Author Interviews, Eli Lilly, Gastrointestinal Disease, NEJM / 02.11.2023
Ulcerative Colitis: FDA Approves Mirikizumab After Study Finds Long Lasting Response
MedicalResearch.com Interview with:
Marla C. Dubinsky, MD
Professor of Pediatrics and Medicine
Icahn School of Medicine at Mount Sinai
Co- director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Health System
MedicalResearch.com: What is the background for this study? Would you briefly describe the condition of UC?
Response: Lucent 1 and Lucent 2 were the induction and maintenance registration trials studying the efficacy and safety of mirikizumab in patients 18 years and older with moderate to severely active ulcerative colitis. Mirikizumab is a monoclonal antibody targeting the p19 subunit of IL23. Lucent-3 is the open label extension arm for those meeting inclusion criteria after completing Lucent 2. This study evaluated the long term efficacy and safety of mirikizumab in patients with ulcerative colitis who completed a total of 104 weeks of active mirikizumab treatment.
Ulcerative colitis is a chronic incurable inflammatory condition of colon. Common symptoms include diarrhea, blood in the stool, abdominal cramping and bowel urgency. Bowel urgency is one of the most burdensome symptoms that a patient with you could experience.
(more…)